Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the approval by the US Food and Drug Administration of a label update for its ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

A Houston neurologist had his medical license suspended following his arrest on charges that accuse him of soliciting a minor ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in weight-loss and diabetes drugs. With a 32% revenue increase in 2024 and ...

Wall Street Zen downgraded Eli Lilly from a "buy" to a "hold" rating, signaling caution amid a flurry of mixed analyst views. Despite this, Eli Lilly still holds strong support from other firms like ...

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.